Suboptimal medical care of patients with ST-Elevation Myocardial Infarction and Renal Insufficiency: results from the Korea acute Myocardial Infarction Registry

Joon Seok Choi¹, Chang Seong Kim¹, Eun Hui Bae¹, Seong Kwon Ma¹, Myung Ho Jeong¹,², Young Jo Kim³, Myeong Chan Cho⁴, Chong Jin Kim⁵ and Soo Wan Kim¹*

Abstract

Background: The clinical outcomes of ST-segment elevation myocardial infarction (STEMI) are poor in patients with renal insufficiency. This study investigated changes in the likelihood that patients received optimal medical care throughout the entire process of myocardial infarction management, on the basis of their glomerular filtration rate (GFR).

Methods: This study analyzed 7,679 patients (age, 63 ± 13 years; men 73.6%) who had STEMI and were enrolled in the Korea Acute Myocardial Infarction Registry (KAMIR) from November 2005 to August 2008. The study subjects were divided into 5 groups corresponding to strata used to define chronic kidney disease stages.

Results: Patients with lower GFR were less likely to present with typical chest pain. The average symptom-to-door time, door-to-balloon time, and symptom-to-balloon time were longer with lower GFR than higher GFR. Primary reperfusion therapy was performed less frequently and the results of reperfusion therapy were poorer in patients with renal insufficiency; these patients were less likely to receive adjunctive medical treatment, such as treatment with aspirin, clopidogrel, β-blocker, angiotensin-converting enzyme (ACE) inhibitor/angiotensin-receptor blocker (ARB), or statin, during hospitalization and at discharge. Patients who received less intense medical therapy had worse clinical outcomes than those who received more intense medical therapy.

Conclusions: Patients with STEMI and renal insufficiency had less chance of receiving optimal medical care throughout the entire process of MI management, which may contribute to worse outcomes in these patients.

Keywords: Myocardial infarction, Optimal medical care, Renal function

Background

Acute coronary syndrome (ACS) is the leading cause of death in patients with chronic kidney disease (CKD) [1,2]. The severity of renal insufficiency, including mild to moderate renal insufficiency is directly associated with increased cardiovascular morbidity and mortality [3,4]. Several factors may be related to poorer outcomes of ACS in patients with renal insufficiency. Hypertension, dyslipidemia, and diabetes mellitus (DM) are common among patients with renal insufficiency and are often inadequately treated in this population [5]. In addition, the accumulation of uremic toxins can stimulate oxidative stress and inflammation, and hence, contribute to endothelial dysfunction and atherosclerosis progression [6].

Primary management in patients with ST-segment elevation myocardial infarction (STEMI) includes timely restoration of flow in the stenosed artery—either by fibrinolysis or by percutaneous coronary intervention (PCI)—to limit the extent of infarction in the myocardium. In addition, medications (anti-platelet agent, β-blocker, angiotensin-converting enzyme [ACE] inhibitor or angiotensin-receptor blocker [ARB] and statin) form...
an important component of evidence-based management. These management strategies have contributed to improved survival in patients with STEMI. However, only a few studies have evaluated how renal function affects the likelihood of receiving optimal medical care throughout the entire treatment period in patients with STEMI.

The purpose of this study was to investigate whether renal insufficiency is associated with a decreased likelihood of receiving optimal medical care in patients with STEMI. The entire medical treatment process for patients with STEMI was comprehensively analyzed, and the relationship between optimal management and clinical outcomes in patients with renal insufficiency was investigated.

Methods
Korea acute myocardial infarction registry
The study population was derived from the Korea Acute Myocardial Infarction Registry (KAMIR). The KAMIR is a prospective, open, observational, multicenter online registry investigating the risk factors for mortality in patients with acute myocardial infarction (AMI) in Korea since November 2005. Through the support of the Korean Circulation Society, 52 community and university hospitals that had facilities for primary PCI and sufficient experience with the procedure participated in KAMIR with the aim of establishing clinical practice guidelines for AMI. The name of each participation centers listed in the Appendix 1 and 2. Data were collected at each site by a trained study coordinator by using a standardized protocol. The study protocol was approved by the ethics committee at each participating institution. All patients gave written informed consent before enrollment.

Study population
This study retrospectively analyzed a cohort of 7,679 consecutive patients who were admitted to the hospital between November 1, 2005, and July 31, 2008, and had a discharge diagnosis of STEMI, confirmed by both cardiac enzyme and electrocardiogram analyses. The diagnosis of STEMI was based on a suggestive history, with ST elevation ≥ 2 mm in ≥ 2 precordial leads, ST elevation ≥ 1 mm in ≥ 2 limb leads, or new left branch bundle block on the 12-lead electrocardiogram with a concomitant increase of cardiac markers ≥ 2 times the upper limit of normal. Patients were excluded if an estimated glomerular filtration rate (GFR) could not be calculated.

Renal function was based on GFR estimation. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to estimate GFR in milliliters per minute per 1.73 m² [7]. The study population was divided into 5 groups according to the estimated GFR; group I, GFR ≥ 90 mL/min/1.73 m² (2099 patients; age, 54 ± 11 years; men, 83.1%); group II, 60 ≤ GFR < 90 mL/min/1.73 m² (3647 patients; age, 63 ± 12 years; men, 75.8%); group III, 30 ≤ GFR < 60 mL/min/1.73 m² (1600 patients; age, 71 ± 11 years; men, 60.6%); group IV, 15 ≤ GFR < 30 mL/min/1.73 m² (210 patients; age, 73 ± 11 years; men, 45.2%); and group V, GFR < 15 mL/min/1.73 m² (123 patients; age, 66 ± 13 years; men, 64.2%).

Data collection
The baseline variables included age; gender; body mass index (BMI); and several coronary risk factors such as hypertension (defined as history of hypertension and admission blood pressure ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic), DM (defined as history of DM or random blood glucose level > 200 mg/dL), hyperlipidemia (defined as history of hyperlipidemia, total cholesterol level of > 240 mg/dL, or low density lipoprotein [LDL] level > 101 mg/dL), history of smoking, history of ischemic heart disease (IHD), clinical symptoms at admission (chest pain or dyspnea), and Killip class. One of the following 3 modalities was selected as primary reperfusion therapy for patients with STEMI: intravenous thrombolytic therapy, primary PCI, or facilitated PCI. The use of certain medications (aspirin, clopidogrel, ACE inhibitor, ARB, β-blocker or statin) during the in-hospital period and at discharge was also recorded. MACE was defined as a composite outcome of cardiac death, repeated PCI, or MI.

Statistical analysis
Continuous variables with normal distributions are expressed as mean ± SD, and the 5 groups were compared using one-way ANOVA. Continuous data with a skewed distribution are presented as median (with 25th and 75th percentiles) and were compared using the Kruskal-Wallis test. Categorical variables were compared using the chi-square test or the Fisher’s exact test if the expected value of the variable was <5 in at least 1 group. Survival analysis after MI was estimated using the Kaplan-Meier method with log-rank tests to compare survival among groups. All statistical tests were 2-tailed, and p < 0.05 was considered significant. Analyses were performed using the Statistical Package for Social Sciences software, version 18.0 (IBM, Armonk, NY USA).

Results
Baseline characteristics
A total of 7,679 patients (age, 63 ± 13 years; men, 73.6%) were included in the present study. The baseline characteristics and biochemical parameters of patients are shown in Table 1. A lower GFR was associated with
older age, female gender, higher prevalence of hypertension, DM, history of IHD, and lower likelihood of being a current smoker. At the time of hospital arrival, a lower GFR was associated with lower blood pressure, lower left ventricular ejection fraction (LVEF), and higher Killip class. In patients with lower GFR, the total cholesterol, LDL, triglyceride, troponin-I, and creatine kinase-MB (CK-MB) levels were lower, whereas the glucose, high sensitivity C-reactive protein (hs-CRP), N-terminal prohormone of brain natriuretic peptide (NT-pro BNP) levels were higher than in patients with higher GFR.

### Table 1 Baseline characteristics

| Group | n | Age, years | Male | BMI (kg/m²) | Hypertension | DM | Previous IHD | Hyperlipidemia | Smoking |
|-------|---|------------|------|------------|--------------|----|-------------|---------------|---------|
| I     | 2099 | 54 ± 11 | 1745(83.1) | 24 ± 3 | 739(35.3) | 445(21.3) | 190(9.1) | 184(8.8) | 1276(61.1) |
| II    | 3647 | 63 ± 12 | 2763(75.8) | 24 ± 3 | 1571(43.2) | 789(21.7) | 420(11.6) | 273(7.5) | 1779(49.1) |
| III   | 1600 | 71 ± 11 | 970(60.6) | 24 ± 3 | 953(59.8) | 505(15.7) | 239(15.1) | 121(7.6) | 493(31.2) |
| IV    | 210  | 73 ± 11 | 95(45.2) | 23 ± 3 | 156(74.6) | 99(47.6) | 39(18.8) | 17(8.1) | 53(25.9) |
| V     | 123  | 66 ± 13 | 79(64.2) | 24 ± 3 | 75(61.5) | 60(48.8) | 29(23.6) | 8(6.6) | 39(32.2) |

| P value | <0.001 | <0.001 | <0.001 | 0.284 |

### Past History

| Hypertension | DM | Previous IHD | Hyperlipidemia | Smoking |
|--------------|----|--------------|----------------|---------|
| 739(35.3)    | 445(21.3) | 190(9.1) | 184(8.8) | 1276(61.1) |
| 1571(43.2)   | 789(21.7) | 420(11.6) | 273(7.5) | 1779(49.1) |
| 156(74.6)    | 99(47.6) | 39(18.8) | 17(8.1) | 53(25.9) |
| 75(61.5)     | 60(48.8) | 29(23.6) | 8(6.6) | 39(32.2) |

### At admission

| SBP (mmHg) | DBP (mmHg) | Killip class | LVEF (%) |
|------------|------------|--------------|----------|
| 130 ± 26   | 81 ± 16    | 1.3 ± 0.7    | 52 ± 11  |
| 127 ± 28   | 78 ± 17    | 1.4 ± 0.8    | 51 ± 12  |
| 117 ± 33   | 72 ± 19    | 1.8 ± 1.1    | 48 ± 13  |
| 111 ± 36   | 70 ± 23    | 2.1 ± 1.2    | 47 ± 14  |
| 123 ± 35   | 75 ± 21    | 2.0 ± 1.2    | 47 ± 12  |

### Biochemical parameters

| Creatinine (mg/dL) | Troponin-I (ng/mL) | CK-MB (U/L) | TC (mg/dL) | LDL (mg/dL) | TG (mg/dL) | Glucose (mg/dL) | hs-CRP (mg/dL) | NT-proBNP (pg/mL) |
|--------------------|--------------------|-------------|-----------|------------|-----------|----------------|----------------|-----------------|
| 0.8 ± 0.1          | 40(7.9)            | 133(38,277) | 188 ± 44  | 122 ± 42   | 109(72,163)| 161 ± 66       | 0.6(0.2,3.4)   | 223(57,871)     |
| 1.0 ± 0.2          | 30(7.68)           | 132(40,283) | 183 ± 43  | 116 ± 42   | 98(66,143)| 168 ± 70       | 0.8(0.2,4.2)   | 346(75,1414)    |
| 1.4 ± 0.3          | 28(5.73)           | 112(26,243) | 175 ± 45  | 112 ± 41   | 95(66,140)| 201 ± 100      | 1.3(0.3,7.0)   | 1144(230,3973)  |
| 2.3 ± 0.5          | 31(10.56)          | 84(27,195)  | 165 ± 42  | 100 ± 39   | 105(74,152)| 234 ± 134      | 4.6(0.8,15.0)  | 5423(1296,21374)|
| 9.5 ± 8.9          | 28(6,51)           | 69(20,176)  | 174 ± 60  | 106 ± 52   | 91(66,150)| 201 ± 106      | 2.1(0.6,9.8)   | 21191(4957,35000)|

### Table 2 Presence of typical chest pain and time of restoration of infarcted-artery

| Group | Presence of chest pain | Symptom to door time, hr | Primary PCI † | Symptom to ballon time, hr | Thrombolysis ‡ |
|-------|------------------------|--------------------------|---------------|---------------------------|----------------|
| I     | 1916(91.8)             | 3.5(1.8,7.7)             | 1.5(1.1,2.9)  | 5.6(3.4,13.0)             | 0.9(0.6,1.5)  |
| II    | 3215(88.7)             | 3.3(1.6,8.2)             | 1.5(1.0,2.3)  | 4.8(3.1,10.1)             | 0.9(0.6,1.4)  |
| III   | 1305(82.2)             | 3.8(1.8,9.7)             | 1.5(1.1,2.4)  | 5.4(3.3,10.8)             | 0.9(0.6,1.4)  |
| IV    | 154(74.4)              | 5.4(2.1,15.5)            | 1.7(1.2,2.6)  | 8.3(4.2,18.4)             | 1.2(0.4,5.8)  |
| V     | 80(66.1)               | 4.8(1.8,16.1)            | 1.9(1.3,4.6)  | 7.2(3.3,26.0)             | 0.8(0.4,-)    |

### Continuous data are expressed as the mean ± SD or the median and interquartile range (25th and 75th percentiles). Categorical data were expressed as percentages. Abbreviations: BMI, body mass index; DM, diabetes mellitus; IHD, ischemic heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; CK-MB, creatine kinase-MB; TC, total cholesterol; LDL, low density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro B-type natriuretic peptide.
Delayed timely restoration of flow in the stenosed artery
Patients with lower GFRs were less likely to present with typical chest pain. The time to restoration of flow in the stenosed artery was analyzed in the following ways: symptom-to-door time in all patients; door-to-balloon time and symptom-to-balloon time in patients who underwent primary PCI as initial reperfusion therapy; door-to-needle time and symptom-to-needle time in patients who received thrombolysis as initial reperfusion therapy (Table 2). Patients with lower GFRs tended to have longer symptom-to-door times. In patients with lower GFRs, door-to-balloon time and symptom-to-balloon time also tended to be longer when primary PCI was the initial reperfusion therapy. In contrast, door-to-needle time and symptom-to-needle time were not significantly different in patients with lower GFRs.

Initial treatment strategy and results of reperfusion therapy
In the initial selection of treatment strategy in patients with STEMI, conservative treatment was more commonly performed but thrombolysis was less frequently performed in patients with lower GFRs (Figure 1). During the in-hospital period, PCI, regardless of its subtype (primary PCI, facilitated PCI, or rescue PCI), was less frequently performed in patients with lower GFR, and its success rate markedly decreased with decrease in GFR (Table 3). In addition, thrombolysis was also performed less frequently in patients with lower GFR, and the success rate of thrombolysis decreased with decrease in GFR.

Angiographic finding
Angiographic findings are shown in Table 4. Multivessel coronary artery disease and disease of the left main coronary artery were more common in groups with lower GFR. Initial TIMI flow 0 (no flow) and presence of a complex lesion (type C) were more frequently observed and a final TIMI flow 3 (complete perfusion) was less frequently observed with lower GFR. Patients with lower GFR were treated with a greater number of stents than patients with higher GFRs.

Table 3 Results of reperfusion therapy

| Result of PCI † | Group I | Group II | Group III | Group IV | Group V | P value |
|----------------|---------|----------|-----------|----------|---------|---------|
| Patients, n    | 1974(95.9) | 3406(94.9) | 1437(91.3) | 181(87.4) | 104(86.0) | <0.001 |
| Success        | 1832(92.8) | 3139(92.2) | 1286(89.5) | 151(83.4) | 86(82.7)  | <0.001 |
| Suboptimal     | 40(2.0)    | 83(2.3)   | 44(3.1)   | 6(3.3)   | 5(4.8)   |         |
| Failed         | 102(5.2)   | 184(5.4)  | 107(7.4)  | 24(13.3) | 13(12.5)  |         |

| Result of thrombolysis ‡ | Group I | Group II | Group III | Group IV | Group V | P value |
|--------------------------|---------|----------|-----------|----------|---------|---------|
| Patients, n              | 290(14.0) | 367(10.2) | 119(7.5)  | 11(5.3)  | 6(5.0)  | <0.001 |
| Success                  | 222(76.6) | 262(71.4) | 83(69.7)  | 3(27.3)  | 3(50.0) | 0.003  |
| Failed                   | 68(23.4)  | 105(28.6) | 36(30.3)  | 8(72.7)  | 3(50.0) |         |

Data are presented as number of patients (percentage). Abbreviations: PCI, percutaneous intervention.

† The subject who received PCI during in-hospital period regardless of its subtype (primary PCI, facilitated PCI, rescue PCI), (n = 7,102).
‡ The subject who received thrombolysis therapy during in-hospital period (thrombolysis only, facilitated PCI), (n = 793).
Intensity of medical treatment

Table 5 lists specific medical treatments received prior to PCI, both during the in-hospital period and at discharge, according to GFR. The use of an anti-platelet agent prior to PCI was not significantly different among the groups. During in-hospital periods, standard medications known to improve survival after MI, such as anti-platelet agent, β-blocker, ACE inhibitor or ARB, and statin were less frequently used in patients with lower GFR. The underuse of these drugs was not corrected until hospital discharge of the patients who survived STEMI. We evaluated the correlation between clinical outcomes and intensity of evidence-based medication in patients with GFR < 60 mL/min/1.73 m². In the hospital period, the patients who received less intense medical therapies had worse clinical outcomes than those who received more intense medical therapies. Similar observations were made for discharge medications among patients who survived STEMI (Figure 2).

Outcomes according to GFR

The clinical outcomes in patients with STEMI are listed in Table 6. At 1 month, MACE and all-cause death were higher in patients with lower GFRs. At 12 months, MACE and all-cause death also increased as decreasing GFRs.

Table 4 Angiographic data

| Number of vessel | Group I | Group II | Group III | Group IV | Group V | P value |
|------------------|---------|----------|-----------|----------|---------|---------|
| One vessel       | 1044(53.2) | 1599(47.2) | 508(35.6) | 42(23.3) | 31(30.1) | <0.001 |
| Two vessel       | 527(26.9)  | 1035(30.6) | 466(32.7) | 66(36.7) | 30(29.1) | <0.001 |
| Three vessel     | 354(18.1)  | 682(20.1)  | 405(28.4) | 62(34.4) | 35(34.0) | <0.001 |
| LM               | 36(1.8)    | 70(2.1)    | 47(3.3)   | 105(5.6) | 7(6.8)   | <0.001 |
| ACC/AHA lesion C | 903(48.9)  | 1625(51.4) | 714(53.8) | 108(65.5) | 57(59.4) | <0.001 |
| Initial TIMI flow grade 0 | 938(49.7) | 1763(54.1) | 772(56.1) | 102(59.3) | 41(41.8) | 0.007 |
| Final TIMI flow grade 3 | 1728(94.3) | 2913(91.6) | 1181(88.1) | 139(84.2) | 76(81.7) | <0.001 |
| Stent number     | 1.40 ± 0.74 | 1.44 ± 0.77 | 1.48 ± 0.81 | 1.49 ± 0.75 | 1.52 ± 0.88 | 0.002 |
| Stent diameter, mm | 3.21 ± 0.42 | 3.21 ± 0.44 | 3.15 ± 0.45 | 3.10 ± 0.43 | 3.22 ± 0.42 | 0.655 |
| Stent length, mm | 25.0 ± 6.3  | 25.1 ± 6.2  | 25.3 ± 6.4  | 26.4 ± 6.8  | 24.7 ± 6.5  | 0.802 |

Data are presented as mean ± SD or number of patients (percentage). Abbreviations: TIMI, Thrombolysis In Myocardial Infarction.

Table 5 Intense of medical therapy

| Pre-PCI medication | Group I | Group II | Group III | Group IV | Group V | P value |
|--------------------|---------|----------|-----------|----------|---------|---------|
| Patients, n        | 1974    | 3406     | 1437      | 181      | 104     | 96      |
| Aspirin            | 796(40.3) | 1366(40.1) | 565(39.3) | 76(42.0) | 53(51.0) | 0.476   |
| Clopidogrel        | 748(37.9) | 1299(38.1) | 528(36.7) | 71(39.2) | 49(47.1) | 0.622   |

| In-hospital medication | Group I | Group II | Group III | Group IV | Group V | P value |
|------------------------|---------|----------|-----------|----------|---------|---------|
| Patients, n            | 2099    | 3647     | 1600      | 210      | 123     |         |
| Aspirin                | 2069(98.6) | 3594(98.5) | 1544(96.5) | 197(93.8) | 118(95.9) | <0.001 |
| Clopidogrel            | 2048(97.6) | 3540(97.1) | 1522(95.1) | 192(91.4) | 114(92.7) | <0.001 |
| β-blocker              | 1619(77.1) | 2581(70.8) | 1003(62.7) | 115(54.8) | 71(57.7) | <0.001 |
| ACEi or ARB            | 1754(83.6) | 2906(79.7) | 1165(72.8) | 132(62.9) | 73(59.3) | <0.001 |
| Statin                 | 1630(77.7) | 2716(74.5) | 1034(64.6) | 125(59.5) | 79(64.2) | <0.001 |

| Discharge medication   | Group I | Group II | Group III | Group IV | Group V | P value |
|------------------------|---------|----------|-----------|----------|---------|---------|
| Patients, n            | 2067    | 3519     | 1373      | 151      | 91      |         |
| Aspirin                | 1980(95.8) | 3300(96.3) | 1303(94.9) | 139(92.1) | 86(94.5) | 0.054   |
| Clopidogrel            | 1927(93.2) | 3276(93.1) | 1266(92.2) | 131(86.8) | 81(89.0) | 0.012   |
| β-blocker              | 1528(73.9) | 2412(68.5) | 921(67.1)  | 99(65.6)  | 58(63.7) | <0.001 |
| ACEi or ARB            | 1691(81.8) | 2789(79.3) | 1070(77.9) | 105(69.5) | 66(72.5) | <0.001 |
| Statin                 | 1577(76.3) | 2610(74.2) | 941(68.5)  | 101(66.9) | 61(67.0) | <0.001 |

Data are presented as number of patients (percentage). Abbreviations: PCI, percutaneous coronary intervention; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Discussions

The principal finding of this study is that patients who have renal insufficiency and develop STEMI are less likely to receive optimal therapy. Patients with renal insufficiency more often presented with atypical symptoms and had longer delays in both hospital arrival and reperfusion. In addition, primary reperfusion therapy was performed less frequently in patients with renal insufficiency and the results of reperfusion therapy were worse with lower GFR. Patients with renal insufficiency were less likely to receive life-saving medical medications such as anti-platelet agent, β-blocker, ACE inhibitor/ARB, or statin during hospitalization and at discharge.

A recent study reported that the probability of patients with MI presenting without chest pain increased proportionally with a decrease in GFR [8]. Canto et al. also showed that patients with MI, but without chest pain, are at increased risk for delays in seeking medical attention, less aggressive treatment, and have higher associated in-hospital mortality [9]. Taken together, these findings suggest that patient with renal insufficiency may have less chance of receiving timely medical care, which

Table 6 Outcomes according to the GFR

|                  | Group I | Group II | Group III | Group IV | Group V | P value |
|------------------|---------|----------|-----------|----------|---------|---------|
| **1 month outcomes** |         |          |           |          |         |         |
| MACE             | 64(3.5) | 217(6.9) | 284(20.6) | 74(41.8) | 37(35.2) | <0.001  |
| All-cause death  | 41(2.0) | 160(4.4) | 263(16.4) | 71(33.8) | 35(28.5) | <0.001  |
| **12 month outcomes** |       |          |           |          |         |         |
| MACE             | 183(8.7)| 382(10.5)| 351(21.9) | 78(37.1) | 46(37.4) | <0.001  |
| All-cause death  | 60(4.4) | 195(8.2) | 304(27.1) | 79(54.9) | 41(48.8) | <0.001  |

Data are presented as number of patients (percentage). Abbreviations: MACE, major adverse cardiovascular event.
may in part be attributed to lack of chest pain. A delay in the time to restoration of flow in the stenosed artery was also observed with lower GFR in patients who had STEMI and underwent primary PCI. Rapid reperfusion is an important goal in the treatment of STEMI patients [10,11]. However, patients with renal insufficiency arrived at the hospital relatively late with respect to symptom onset, and clinicians may be reluctant to make an immediate decision in patients with renal insufficiency because of the presence of more comorbidities and increased complexity of medical care.

During the hospital period, reperfusion therapy, regardless of its subtype, was used less frequently in patients with lower GFR, which was consistent with previous studies [12,13]. Older age, more comorbidities, compromised hemodynamic status, and fear of complications such as bleeding and contrast-induced nephropathy may all affect a clinician's decision. In addition, the results of reperfusion therapy were disappointing in patients with renal insufficiency. A higher incidence of multivessel disease, more complex lesions, and poor coronary blood flow before and after PCI may contribute to the poor results of reperfusion therapy. Although the exact pathophysiologic mechanisms by which renal insufficiency adversely affect the results of reperfusion therapy have not been clearly elucidated, oxidative stress, endothelial cell dysfunction, and more advanced atherosclerosis may play a role in this regard [14-17].

Although, renal insufficiency is an important risk factor for increased mortality, patients with lower GFR were less likely to receive adjunctive medical therapies recommended by current guidelines. This finding is consistent with previous reports [18,19]. The underuse of life-saving medications may result from fear of adverse effects. Clinicians are often reluctant to use an antiplatelet agent for patients with renal insufficiency because of the risk of bleeding. Similarly, hyperkalemia or renal function deterioration often pushes clinicians to withhold ACE inhibitor/ARB therapy. However, evidence indicates that these medications are associated with great survival benefits in patients with renal insufficiency, even in the case of severe renal insufficiency [20-22]. In clinical practice, clinicians who assess the risks and benefits of medication should consider the fact that the long-term cardioprotective and survival benefits outweigh the risk associated with short-term adverse effects.

The mortality rate associated with MI has fallen considerably in recent decades [23,24]. Improvements in emergency system response times and diagnostic techniques may explain some of the improvements in MI mortality. Advances in medical treatment and cardiac interventions have also played a role in this improvement. Despite these advances, data from this study indicate that patients with renal insufficiency were less likely to receive optimal medical care throughout the entire process of MI management and that these differences may contribute to worse outcomes in patients from the KAMIR data population who had lower GFR and developed MI [4,25].

The present study has some limitations. First, KAMIR is a multicenter retrospective registry study and not a randomized controlled study. Therefore, unmeasured factors in the KAMIR database could influence these findings. Second, assessment of kidney function in this study was based on a single serum creatinine value obtained at the time of presentation to the hospital. This value may have been affected by hemodynamic or metabolic status. Third, although, estimating GFR based on serum creatinine are preferable method for accessing renal function in the clinical practice, it is influenced by various factors such as age, gender, ethnics, muscle mass and nutritional status. This could confound the relationship between GFR and likelihood of receiving optimal medical care in patients with STEMI.

**Conclusion**

In conclusion, patients with STEMI and renal insufficiency had significantly less chance of receiving optimal medical care throughout the entire process of MI management. Despite recent advances in emergency systems and evidence-based therapy, these advances have been applied less frequently in patients with renal insufficiency than in patients with normal renal function. Therefore, patients with renal insufficiency require an aggressive approach to diagnosis, intervention, and medical treatment for improved clinical outcomes.

**Appendix 1**

**Korea Acute Myocardial infarction Registry (KAMIR) Investigators**

Myung Ho Jeong MD, Young Keun Ahn MD, Sung Chull Chae MD, Jong Hyun Kim MD, Seung Ho Hur MD, Young Jo Kim MD, In Whan Seong MD, Dong Hoon Choi MD, Jei Keon Chae MD, Taek Jong Hong MD, Jae Young Rhee MD, Doo Il Kim MD, In Ho Chae MD, Jung Han Yoon MD, Bon Kwon Koo MD, Byung Ok Kim MD, Myoung Yong Lee MD, Kee Sik Kim MD, Jin Yong Hwang MD, Myeong Chan Cho MD, Seok Kyu Oh MD, Nae Hee Lee MD, Kyoung Tae Jeong MD, Seung Jea Tahk MD, Jang Ho Bae MD, Seung Woon Rha MD, Keum Soo Park MD, Chong Jin Kim MD, Kyoo Rok Han MD, Tae Hoon Ahn MD, Moo Hyun Kim MD, Ki Bae Seung MD, Wook Sung Chung MD, Ju Young Yang MD, Chong Yun Rhim MD, Hyeon Cheol Gwon MD, Seong Wook Park MD, Young Youp Koh MD, Seung Jae Joo MD, Soo Joong Kim MD, Dong Kyu Jin MD, Jin Man Cho MD, Byung Ok Kim MD, Sang-Wook Kim MD, Jeong Kyung Kim MD, Tae Ik Kim MD, Deug
Young Nah MD, Si Hoon Park MD, Sang Hyun Lee MD, Seung Uk Lee MD, Hang-Jae Chung MD, Jang Hyun Cho MD, Seung Won Jin, MD, Yang Soo Jang MD, Jeong Gwan Cho, MD and Seung Jung Park MD.

Appendix 2

Korea Acute Myocardial infarction Registry (KAMIR) participation centers

- Seoul St. Mary’s Hospital, Kangdong Sacred Hospital, Konyang University Hospital, Kyungpook National University Hospital, Gyeongsang National University Hospital, Kyunghee Dongsuh University Hospital, Kyunghee University Medical Center, Korea University Guro Hospital, Kwangju Christian Hospital, National Health Insurance Corporation Ilsan Hospital, Dankook University Hospital, Daegu Catholic University Medical Center, Daejeon Sun Hospital, Daejeon St. Mary’s Hospital, Dongguk University Gyeongju Hospital, Dongsan Medical Center, Dong-A University Medical Center, Mokpo Hankuk Hospital, Kwangju Veterans Hospital, Busan National University Hospital, Busan Marynoll Medical Center, Busan Paik Hospital, Busan Hanseo Hospital, Seoul National University Bundang Hospital, Samsung Medical Center, Inje University Sanggye Paik Hospital, Seoul National University Hospital, Asan Medical Center, St. Paul’s Hospital, St. Carollo Hospital, Soon Chun Hyang University Bucheon Hospital, Soon Chun Hyang University Cheonan Hospital, Yonsei University Severance Hospital, Ajou University Hospital, Yeouido St. Mary’s Hospital, Yeungnam University Medical Center, Wonkwang University School of Medicine & Hospital, Wonju University Hospital, Eulji Medical Center, Ewha Womans University Mokdong Hospital, Gachon University Gil Hospital, Inha University Hospital, Chonnam National University Hospital, Chonbuk National University Hospital, Presbyterian Medical Center, Jeju National University Hospital, Chosun University Hospital, Chung Ang University Hospital, Chungnam National University Hospital, Chungbuk National University Hospital, Pohang Seomyung Christianity Hospital, Hallym University Medical Center.

Competing interests

The authors declared that they have no competing interest.

Authors’ contributions

JSC and SWK designed research, performed, and wrote the paper. CSK, EHB, and SKM interpreted the data. MHJ, YJK, MCC and CJK were investigators of Korea Acute Myocardial infarction Registry. All authors read and approved the final manuscript.

Acknowledgements

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011–0009743), and by the Korea Science and Engineering Foundation through the Medical Research Center for Gene Regulation grant (2012–0009448) at Chonnam National University.

Author details

1Department of Internal Medicine, Chonnam National University Medical School, 42 Jejubong, Gwangju 501–757, South Korea. 2Cardiovascular Research Institute of Chonnam National University, Gwangju, South Korea. 3Department of Internal Medicine, Yonju University, Daegu, South Korea. 4Department of Internal Medicine, Chungbuk National University, Cheongju, South Korea. 5Department of Internal Medicine, Kyunghee University, Seoul, South Korea.

Received: 4 March 2012 Accepted: 22 August 2012
Published: 11 September 2012

References

1. VI. Causes of death in ESRD. Am J Kidney Dis 1999, 34(2 Suppl 1):S87–S94.
2. Wolfe RA, Port FK, Webb RL, Bloembergen WE, Hirth R, Young EW, Ojo AD, Strawderman RL, Parekh R, Stack A, et al. Introduction to the excerpts from the United States Renal Data System 1999 Annual Data Report, Am J Kidney Dis 1999, 34(2 Suppl 1):S1–S3.
3. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004, 351(13):1285–1295.
4. Bae EH LS, Cho KH, Choi JS, Kim CS, Park JW, Ma SK, Jeong MH, Kim SW: Glomerular filtration rate and cardiovascular outcomes after acute myocardial infarction: Results from Korea Acute Myocardial infarction Registry. American J Kidney Dis 2012, 59(6):795–802.
5. Panikh N, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med 2005, 166(17):1884–1891.
6. Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340(2):115–126.
7. Skall H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD: Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J 2011, 162(3):S54–S55.
8. Choi JS KC, Park JW, Bae EH, Ma SK, Jeong MH, Kim SW: Renal Dysfunction as a Risk Factor for Painless Myocardial Infarction: Results from Korea Acute Myocardial Infarction Registry. Clin Res Cardiol. Epub ahead of print.
9. Canto JG, Shlipak MG, Rogers WJ, Malmgren JA, Frederick PD, Lambrew CT, Orrato JP, Barron HV, Kiefie CJ: Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 2000, 283(24):3223–3229.
10. Ross AM, Coyne KS, Moreyta E, Reiner JS, Greenhouse SW, Walker PL, Simoons ML, Druoci YC, Califf RM, Topol EJ, et al: Extended mortality benefit of early postinfarction reperfusion, GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998, 97(6):1549–1556.
11. Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutshu WR, Vahanian A, Simoons ML, Morris D, Betrua A, Califf RM: Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995, 91(7):1923–1928.
12. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, Granger CB, Ohrman EM, Holmes DR Jr: Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002, 106(8):974–980.
13. Santopinto JI, Fox KA, Goldberg RJ, Budaj A, Pinero G, Avezum A, Gulba D, Esteban J, Gore JM, Johnson J, et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart 2003, 89(9):1003–1008.
14. Becker PN, HimmelFarb J, Henrich WL, Hakon RM: Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997, 8(3):475–486.
15. Cauz E, Kletzmaier J, Bodzial G, Dunky A, Herrmann W, Kostner K: Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function. Nephrol Dial Transplant 2003, 18(6):1568–1572.
16. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R: Circulating thrombomodulin levels are related to latent progression of atherosclerosis in hypertensive patients. Hypertens Res 2003, 26(6):479–483.

17. Fleck C, Schwetzler F, Karge E, Busch M, Stein G: Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta 2003, 336(1–2):1–12.

18. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kepecsy SL, Jaffe AS: Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002, 137(7):563–570.

19. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD: Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 2010, 121(3):357–365.

20. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M: Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med 2000, 160(17):2645–2650.

21. Shlipak MG, Browner WS, Noguchi H, Massie B, Frances CD, McClellan M: Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Am J Med 2001, 110(6):425–433.

22. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003, 42(2):201–208.

23. McGovern PG, Folson AR, Sparafaka JM, Burke GL, Doliszny KM, Demirovic J, Naylor JD, Blackburn H: Trends in survival of hospitalized myocardial infarction patients between 1970 and 1985. The Minnesota Heart Survey. Circulation 1992, 85(1):172–179.

24. Kilburn H Jr, Schoen L, Wang T: Acute Myocardial Infarction in New York State: 1996–2008. J Community Health 2011, 36(2):473–479.

25. Lee SH, Kim YI, Kim W, Park JS, Shin DG, Hur SH, Kim CJ, Cho MC, Chae SC, Jeong MH, et al: Clinical outcomes and therapeutic strategy in patients with acute myocardial infarction according to renal function: data from the Korean Acute Myocardial Infarction Registry. Circ J 2008, 72(9):1410–1418.

Cite this article as: Choi et al.: Suboptimal medical care of patients with ST-Elevation Myocardial Infarction and Renal Insufficiency: results from the Korea acute Myocardial Infarction Registry. BMC Nephrology 2012 13:110.